– Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p<0.0001) – – 87.1% of Patients Treated with Combination of Obicetrapib and Ezetimibe Met Guideline-Recommended LDL-C Goal of <55 mg/dL compared to 0% of Patients Treated with Placebo (p<0.05) – – New […]

— Achieved primary endpoint with statistically significant reduction in LDL-C (p < 0.0001) — — Median percent change in LDL-C of -59% in combination arm compared to -6% in placebo arm — — Favorable safety and tolerability — — Data […]